- Home
- CERO vs KTTA Comparison
CERO vs KTTA Comparison
Compare CERO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- KTTA
- Stock Information
- Founded
- CERO 2017
- KTTA 2020
- Country
- CERO United States
- KTTA United States
- Employees
- CERO N/A
- KTTA N/A
- Industry
- CERO
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- KTTA Health Care
- Exchange
- CERO Nasdaq
- KTTA Nasdaq
- Market Cap
- CERO 6.1M
- KTTA 5.5M
- IPO Year
- CERO N/A
- KTTA 2021
- Fundamental
- Price
- CERO $1.99
- KTTA $0.73
- Analyst Decision
- CERO Strong Buy
- KTTA
- Analyst Count
- CERO 2
- KTTA 0
- Target Price
- CERO $45.00
- KTTA N/A
- AVG Volume (30 Days)
- CERO 291.2K
- KTTA 83.2K
- Earning Date
- CERO 11-18-2025
- KTTA 11-12-2025
- Dividend Yield
- CERO N/A
- KTTA N/A
- EPS Growth
- CERO N/A
- KTTA N/A
- EPS
- CERO N/A
- KTTA N/A
- Revenue
- CERO N/A
- KTTA N/A
- Revenue This Year
- CERO N/A
- KTTA N/A
- Revenue Next Year
- CERO N/A
- KTTA N/A
- P/E Ratio
- CERO N/A
- KTTA N/A
- Revenue Growth
- CERO N/A
- KTTA N/A
- 52 Week Low
- CERO $1.93
- KTTA $0.65
- 52 Week High
- CERO $895.40
- KTTA $4.57
- Technical
- Relative Strength Index (RSI)
- CERO 14.42
- KTTA 44.70
- Support Level
- CERO $5.18
- KTTA $0.70
- Resistance Level
- CERO $5.66
- KTTA $0.81
- Average True Range (ATR)
- CERO 0.42
- KTTA 0.04
- MACD
- CERO -0.26
- KTTA -0.01
- Stochastic Oscillator
- CERO 1.61
- KTTA 22.14
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).